BIOMAT Database Logo BIOMAT Database Logo

Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. 1994

M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
First Department of Internal Medicine, Osaka City University Medical School, Japan.

We investigated the protective effect of angiotensin II (Ang II) type 1 receptor antagonist on myocardial ischemia-reperfusion injury and the role of exogenous Ang II to this injury in perfused hearts. We orally administered TCV-116 (Ang II type 1 receptor antagonist) and delapril (angiotensin converting enzyme inhibitor) to Wistar rats for 1 week and measured the immunoreactive cardiac Ang II. Immunoreactive cardiac Ang II (pg/gm tissue) was 14.3 +/- 2.0 in control group, 11.8 +/- 0.8 in TCV-116-treated group, and 7.3 +/- 0.6 in delapril-treated group (p < 0.05 compared to TCV-116-treated group; p < 0.01 compared to control group). The 15 hearts (five rats in each group) were perfused by a langendorff method and global ischemia was maintained for 30 min. Both TCV-116 and delapril were found to improve postischemic cardiac function and decrease reperfusion creatine kinase (CK) release. Ang II injection before ischemia worsened postischemic cardiac function and increased reperfusion CK release. Only TCV-116 prevented this injury. These data indicated that TCV-116 Ang II type 1 receptor antagonist was effective against myocardial ischemia-reperfusion injury, and exogenous Ang II accelerated this injury through Ang II type 1 receptor.

UI MeSH Term Description Entries
D007189 Indans Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES. Indanones
D008297 Male Males
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D003402 Creatine Kinase A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins. Creatine Phosphokinase,ADP Phosphocreatine Phosphotransferase,ATP Creatine Phosphotransferase,Macro-Creatine Kinase,Creatine Phosphotransferase, ATP,Kinase, Creatine,Macro Creatine Kinase,Phosphocreatine Phosphotransferase, ADP,Phosphokinase, Creatine,Phosphotransferase, ADP Phosphocreatine,Phosphotransferase, ATP Creatine
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats.
February 2002, Transplantation,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Open clinical studies on a new angiotensin II receptor antagonist, TCV 116.
November 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury.
January 1994, Blood pressure. Supplement,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog.
April 1999, Japanese journal of pharmacology,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers.
January 1995, Hypertension (Dallas, Tex. : 1979),
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
January 1994, Blood pressure. Supplement,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters.
December 1994, The American journal of physiology,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Effect of an angiotensin II receptor antagonist, TCV-116, on neointimal formation following balloon injury in the SHR carotid artery.
December 1995, Clinical and experimental pharmacology & physiology. Supplement,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Cardioprotective effects of angiotensin II type 1 receptor blockade with olmesartan on reperfusion injury in a rat myocardial ischemia-reperfusion model.
January 2010, Cardiovascular therapeutics,
M Yoshiyama, and S Kim, and H Yamagishi, and T Omura, and T Tani, and S Yanagi, and I Toda, and M Teragaki, and K Akioka, and K Takeuchi
Angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats.
January 1994, Blood pressure. Supplement,
Copied contents to your clipboard!